Human γ-interferon expression in the mammary gland of transgenic mice  by Dobrovolsky, V.N. et al.
Volume 319, number 1,2, 181-184 FEBS 12239 
0 1993 Federation f European Biochemical Societies 00145793/93/$6.00 
March 1993 
Human y-interferon expression in the mammary gland of transgenic mice 
V.N. Dobrovolsky”, O.V. Lagutin”, T.V. Vinogradova”, I.S. Frolovab, V.P. Kuznetsovb and O.A. Larionova 
“Shemyakin Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia and bGamaleya Institute for Epidemi- 
ology and Microbiology, Russian Academy of Medical Sciences, Moscow, Russia 
Received 5 January 1993; revised version received 19 January 1993 
Transgenic mice carrying a hybrid gene consisting of ovine/I-lactoglobulin gene sequences and human y-interferon (hIFN-g) cDNA were produced. 
hIFN-g expression in the mammary gland of two lactating transgenic founder females was found. The concentration of active hIFN-g in the milk 
was estimated as being ca. 1800 IUlml. The hIFN-g ability to express in the mammary gland was found m the progeny of transgenic founder male. 
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1. INTRODUCTION 
The human y-interferon (hIFN-g) is an immunomod- 
ulator displaying antiviral and antiproliferative proper- 
ties [l]. The recombinant non-glycosylated hIFN-g ex- 
pressed in E. coli cultures can presently be purchased on 
the market from various sources. But the medical use 
of the non-glycosylated hIFN-g seems however to be 
limited, because the recombinant non-glycosylated pro- 
teins are known to possess the immunogenic activity (as 
is, for example, the case in granulocyte/macrophage col- 
ony stimulating factor [2]). 
One way to obtain large amounts of glycosylated 
hIFN-g is to develop transgenic forms of domestic 
mammal species able to synthesize the protein in their 
mammary glands. Obviously, prior to the commercial 
application of the mentioned approach, the possibility 
of the synthesis of biologically active hIFN-g in the 
mammary gland and of its secretion into the milk is to 
be proved on laboratory animals. 
Here we report the results of the development of a 
hybrid gene intended for expression of the hIFN-g in 
the mammary gland of transgenic animals and prove 
the presence of biologically active interferon in the milk 
samples taken from transgenic mice carrying such a 
gene. 
terminating codons and was identical in nucleotide sequence to previ- 
ously published sequence [4]. The GC-tails were removed from the 
cDNA ends by site-directed mutagenesis [5]. The ovine genomic li- 
brary in the phage lambda EMBL-3 was produced according to [6], 
the genomic DNA being isolated from the ovine liver. For the screen- 
ing of the library and /I-lactoglobulin (BLG) gene searching the par- 
tially overlapping oligonucleotides ON1 (5’-GTGGCGTCCAGGC- 
CATCATCGTC-3’) and ON2 (S-TITCATGGTCTGGGTGAC- 
GATGATGG-3’) (Fig. 1A) complementary to the already established 
cDNA sequence of BLG gene [7] were used as probes. The SukXbuI 
fragment of the DNA containing the ovine BLG gene and flanking 5’ 
and 3’ sequences (Fig. IA) was finally isolated. The BLG gene frag- 
ment containing untranslated region of the penultimate xon, the last 
mtron, and the last exon of BLG gene (including polyadenylation 
signal) was amplified using polymerase chain reaction (PCR) [8] with 
two oligonucleotides, ON3 (Y-TACGTAGGTGAGCCCCTGCCG- 
GTGC-3’) and ON4 (S-AAGCTTCCAGCAAAGACTCAGAAGG- 
3’) (Fig. IA). They contained at their 5’-ends recognition sequences for 
restriction endonucleases SnuBI and Hind111 and were complemen- 
tary to flanks of the BLG gene fragment [9]. The amplified fragment 
(616 bp) bearing newly created sites SnuBI at its 5’-end and Hind111 
at its 3’-end, was ligated into the PvuII site that resides within the 
untranslated region of the BLG gene first exon (Fig. 1A). hIFN-g 
cDNA was inserted into SnuBI site (Fig. 1B). Thus derived BLG- 
hIFN-g hybrid gene (Fig. 1C) was then used to produce transgenic 
mice. 
2.2. Production and identifcutlon of transgenic mice 
2. MATERIALS AND METHODS 
2.1. Construction of the hybrid gene 
A full-length hIFN-g cDNA has been cloned from a human spleen 
cDNA library as described in [3]. It contained both initiating and 
200 to 400 copies of the hybrid gene BLG-hIFN-g had been micro- 
injected into the NMRI mice zygote pronuclei; 1 100 injected zygotes 
were transplanted into oviducts of pseudopregnant females; genomic 
DNA was isolated from tails of 90 two-week-old mice, developed from 
microinjected zygotes [lo]. To detect he presence of exogenous DNA 
in the mouse genome, a PCR [1 1] was conducted using oligonucleo- 
tides ON5 (5’-AATGCAGGTCATTCAGATGTAGCGG-3’) and 
ON6 (5’-CGAATAAITAGTCAGCTTTTCGAAG-3’) as primers 
which were complementary to the hIFN-g cDNA (Fig. 1C). 
2.3. RNA isolation and analysis 
Correspondence address: O.A. Larionov, Shemyakin Institute of 
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Maklaya, 16110, 117871 GSP Moscow, V-437 Russia. Fax: (7) (095) 
330-64-65. 
RNA from lactating mammary gland and other organs was isolated 
as described in [12]. The isolated total RNA was analysed by applica- 
tion of reversed transcription followed by PCR (RT-PCR) [9]. RNA 
was submitted to the reversed transcription reaction in the presence 
of M-MuLV reverse transcriptase with ON7 (5’-CCCAGAGGAGT- 
CCAAGGCTCCCGGG-3’) (Fig. 1C) as primer. The obtained cDNA 
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Fig. 1. Sketch of the hybrid BLG-hIFN-g gene construction. (A) Structure of cloned BLG gene and locahzatton of primers ONl, ON2,ON3,ON4. 
The long angled arrow indicates the insertion site of amplified fragment of the BLG gene within the untranslated region of the first exon of the 
BLG gene. Numbered boxes are exons of the BLG gene, solid lines: introns of BLG gene; shaded boxes: 5’ and 3’ flanking sequences of the BLG 
gene; short horizontal arrows: primers; bent-off ends of short arrows: non-complementary fragments of primers ON3 and 0N4, containing 
recognition sites for restriction endonucleases SnuBI and HlndIII, respectively. (B) Insertion of the hIFN-g cDNA into the SnuBI site under the 
control of the BLG gene promoter. C. Structure of the hybrid gene BLG-hIFN-g, used for microinjections, and localization of primers ON5, 
ON6, 0N7. 
was used in PCR in the presence of oligonucleotides ON5 and ON7 
(Fig. 1C) [13]. 
3. RESULTS AND DISCUSSION 
2.4. Analysis of the milk samples 
Milk was collected from transgemc lactating mice 12-14 days after 
partuntion. Milk samples were diluted 1:2 in distilled water and defat- 
ted by repeated centrifugation (12 000 x g). The determination of 
interferonic activity was based on protection of a human fibroblasts 
monolayer culture against the cytopathic effects of vesicular stomatitis 
virus strain Indiana [14]. hIFN-g titers in milk samples were calculated 
in international units (IU) according to international reference Stand- 
ard Gg23-901-530. 
The BLG-hIFN-g hybrid gene was created (Fig. 1). 
When creating the hybrid gene based on cloned BLG 
gene and hIFN-g cDNA we aimed to retain all the 
possible regulatory sequences of the BLG gene which 
could presumably be present in its introns and exons. 
Nine transgenic founder mice (four females and five 
males) having BLG-hIFNg hybrid genes were pro- 
duced. To identify the transgene within mouse genomic 
Fig. 2. Identification of transgenic mice by PCR analysis. (1) marker pBR322/HinfI; (2) negative control (DNA of mouse NMRI); (3) DNA of 
mouse 26; (4) DNA of mouse 28; (5) DNA of mouse 30; (6) DNA of mouse 34; (7) DNA of mouse 40; (8) DNA of mouse 45; (9) DNA of mouse 
53; (10) DNA of mouse 65; (11) DNA of mouse 71; (12) DNA from human placenta; (13) positive control (hybrid gene BLG-hIFN-g used for 
microinjections); (14) marker pBR322/HznfI. Arrows show the amplified DNA fragments, whose lengths of 252 bp and 346 bp are calculated 
according to nucleotide sequences of hIFN-g cDNA and genomtc gene of hIFN-g. respectively. 
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Fig. 3. RT-PCR analysis of RNA isolated from the mammary glands 
of transgenic females. (1) marker pBR32UHinfI; (2) negative control 
(RNA of mouse NMRI); (3) RNA of mouse 26; (4) RNA of mouse 
28; (5) RNA of mouse 34; (6) RNA of mouse 71. Arrow shows the 
amplified DNA fragment, whose length (462 bp) is calculated accord- 
ing to nucleotide sequences of hIFN-g cDNA and ovine BLG genomic 
gene. 
DNA, we conducted PCR, which is known to provide 
a rapid screening method for transgenic mice [7]. The 
results of transgene identification within the mouse 
genome are displayed in Fig. 2. Eight out of nine foun- 
der transgenic mice have transmitted the transgene to 
their progeny (Table I). The offspring of founder mouse 
65 was also tested for ability to transmit the transgene 
to their progeny (Table I). 
Expression of the transgene was found in the mam- 
mary gland of lactating founder transgenic mice 26 and 
28: the hybrid BLG-hIFN-g mRNA was detected in the 
mammary gland tissue (Fig. 3) and an interferonic ac- 
tivity of about 1,800 III/ml was observed in the milk 
samples (Table I), which corresponds to the hIFN-g 
concentration of about 20 &ml, assuming an hIFN-g 
specific activity to be ca. 1~10~ IU/mg. The interferonic 
activity was observed also in the mammary gland of 
lactating transgenic females 65.37, 65.38, and 65.39 de- 
scended from transgenic male 65 (Table I). 
The transgenic lactating female 65.39 was tested for 
tissue specificity of transgene expression. The hybrid 
mRNA of BLG-hIFN-g was found in the mammary 
gland tissues, but not in lung, liver and kidney (data not 
shown). 
The low observed level of hIFN-g expression (ca. 
1,800 IU per ml of milk) seems to be due to the absence 
of introns of the genomic gene hIFN-g in the hybrid 
transgene. Indeed, it was reported that in some experi- 
ments the genomic gene containing introns and forming 
a part of a hybrid gene is expressed in transgenic ani- 
mals more effectively than the cDNA [15]. This is the 
reason to produce a new hybrid gene containing as 
structural element he genomic hIFN-g gene. 
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